| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Laboratory of Tumor Immunology and Biology, 2 Biostatistics and Data Management Section, National Cancer Institute, NIH, Bethesda, Maryland; and 3 Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia
Requests for reprints: Scott I. Abrams, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room 5B46, 10 Center Drive, Bethesda, MD 20892-1402. Phone: 301-496-4343; Fax: 301-496-2756; E-mail: sa47z{at}nih.gov.
IFN regulatory factor (IRF)-8 plays an important role in normal myelopoiesis. The loss of IRF-8 in myeloid cells results in a chronic myelogenous leukemia–like syndrome, suggesting that IRF-8 behaves as a tumor suppressor gene in certain hematopoietic malignancies. We have been investigating the molecular determinants of solid tumor progression, with an emphasis on apoptotic resistance. Recently, we showed that IRF-8 expression was directly correlated with Fas-mediated apoptosis, and inversely related to malignant phenotype. However, the functional role of IRF-8 in solid tumors is unresolved. We stably silenced IRF-8 expression via RNA interference in IRF-8–expressing mouse tumor cells, and evaluated them for changes in apoptotic phenotype and malignant behavior. Apoptosis induced by Fas engagement or irradiation was markedly reduced in IRF-8–deficient tumor cells, despite unaltered proliferation, cell surface Fas, or MHC class I expression. Moreover, in syngeneic immunocompetent mice, IRF-8–deficient tumor cells grew more aggressively than their control counterparts. However, in IFN-
– or Fas ligand–deficient mice, but not T cell–deficient mice, both control and IRF-8–deficient tumor populations grew similarly. Furthermore, both tumor populations grew similarly in mice with defects in innate immunity. Although subsequent studies precluded a role for natural killer cells, immunohistochemical analysis supported the involvement of macrophages. Overall, our findings show that IRF-8 expression in solid tumor cells is important for efficient host immunosurveillance and response to apoptotic stimuli. Therefore, IRF-8 down-regulation may represent a previously unrecognized tumor escape mechanism that facilitates tumor progression. Conversely, strategies aimed at up-regulating or restoring IRF-8 expression in neoplastic cells may improve therapeutic efficacy. [Cancer Res 2007;67(21):10406–16]
This article has been cited by other articles:
![]() |
I. N. Buhtoiarov, A. L. Rakhmilevich, L. L. Lanier, E. A. Ranheim, and P. M. Sondel Naive Mouse Macrophages Become Activated following Recognition of L5178Y Lymphoma Cells via Concurrent Ligation of CD40, NKG2D, and CD18 Molecules J. Immunol., February 15, 2009; 182(4): 1940 - 1953. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yang, S. Wang, C. Brooks, Z. Dong, P. V. Schoenlein, V. Kumar, X. Ouyang, H. Xiong, G. Lahat, A. Hayes-Jordan, et al. IFN Regulatory Factor 8 Sensitizes Soft Tissue Sarcoma Cells to Death Receptor-Initiated Apoptosis via Repression of FLICE-like Protein Expression Cancer Res., February 1, 2009; 69(3): 1080 - 1088. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. McGough, D. Yang, S. Huang, D. Georgi, S. M. Hewitt, C. Rocken, M. Tanzer, M. P.A. Ebert, and K. Liu DNA Methylation Represses IFN-{gamma}-Induced and Signal Transducer and Activator of Transcription 1-Mediated IFN Regulatory Factor 8 Activation in Colon Carcinoma Cells Mol. Cancer Res., December 1, 2008; 6(12): 1841 - 1851. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |